Table 2

Univariate analysis of the relation between preoperative characteristics and survival of 146 patients with pancreatic cancer

Clinicopathological variable	Patients n (%)	1 year CS (%)	95% CI	2 year CS (%)	95% CI	5 year CS (%)	95% CI	χ²	p Value
CI, confidence interval; CS, cumulative survival; NA, not available.
Tenascin
Negative (⩽5%)	12 (8)	56	26–85	19	0–2	0	0–0	<0.01	1.0
Faint (>5–20%)	72 (49)	42	30–53	21	12–30	6	0–11
Moderate (>20–60%)	52 (36)	54	40–67	25	13–37	9	0–16
Strong (>60%)	10 (7)	10	0–29	0	0–0	0	0–0
Tenascin
⩽20%	84 (58)	44	33–54	21	12–29	5	0–10	0.9	0.34
>20%	62 (42)	47	34–60	21	11–31	7	0–14
Sex
Female	81 (55)	46	36–57	21	12–30	6	0–12	0.03	0.9
Male	65 (45)	43	31–55	20	10–30	5	0–11
Age (years)
⩽66	73 (50)	52	40–63	26	16–37	9	2–16	5.0	0.03
>66	73 (50)	38	27–50	15	7–23	3	0–7
Tumour location
Head	129 (88)	47	38–56	23	15–30	7	2–11	4.3	0.04
Other	15 (10)	33	10–57	7	0–19	0	0–0
NA	2 (1)
TNM stage
I	27 (18)	67	49–84	33	16–51	11	0–23	9.9	0.002
II	48 (33)	46	32–60	27	15–40	6	0–13
III	29 (20)	39	21–58	18	4–32	7	0–17
IV	41 (28)	32	18–46	7	0–15	0	0–0
NA	1 (1)
Tumour size
⩽2 cm	26 (18)	68	50–87	20	4–36	0	0–0	3.3	0.07
>2–4 cm	73 (50)	51	39–62	25	15–35	10	3–17
>4 cm	32 (22)	19	5–32	13	1–24	3	0–9
NA	15 (10)
Tumour stage
1	9 (6)	78	51–100	22	0–49	0	0–0	3.3	0.07
2	28 (19)	46	28–65	32	15–49	11	0–22
3	73 (50)	43	32–55	22	13–32	7	1–13
4	35 (24)	37	21–53	9	0–18	0	0–0
NA	1 (1)
Lymph node metastasis
N0	90 (62)	56	45–66	27	18–36	7	2–12	3.4	0.07
N1	42 (29)	32	18–46	15	4–26	7	0–15
NA	14 (10)
Distant metastasis
M0	135 (92)	48	39–56	22	15–30	6	2–11	14.7	0.0001
M1	10 (7)	10	0–29	0	0–0	0	0–0
NA	1 (1)
Curativity
Intent to cure	94 (64)	56	46–66	29	20–38	9	3–14	18.1	<0.0001
Non-curative	52 (36)	25	13–37	6	0–12	0	0–0
Grade of differentiation
1	15 (10)	80	60–100	40	15–65	27	4–49	16.3	<0.0001
2	92 (63)	47	37–58	23	15–32	6	0–10
3	39 (27)	26	12–39	8	1–16	0	0–0